Form 4 for ATRA Atara Biotherapeutics, Inc.
Accepted 2026-08-26 19:45:25 ET · period of report 2026-08-17 · accession 0000905148-26-003960 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-08-26 19:45 | 2026-08-17 | ATRA | Nguyen AnhCo | Pres, CEO, Dir | S - Sale | $8.08 | -5,062 | 132.8K | -4% | -$40.9K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-08-17 | S | D | 5,062 | $8.08 | 132,775 | D | — | — | (F1) Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement. (F2) The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on August 17, 2026, on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees. |